ASCO 2023 | Unanswered questions in the use of mRNA-based personalized cancer vaccines

Adnan Khattak, MBBS, FRACP, Royal Perth Hospital, Perth, Australia, provides an overview of the role of personalized cancer vaccines in the management of melanoma, highlighting an upcoming Phase III trial of mRNA-4157, a novel mRNA-based personalized cancer vaccine in comparison to pembrolizumab monotherapy. Unanswered questions in the use of mRNA-based personalized cancer vaccines include identifying patients likely to respond to vaccine therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.